Share This Article

Human biospecimens are essential to advancing biomedical research—but they also carry significant ethical and legal responsibilities.

Behind every sample is a donor. And behind every study is an obligation to ensure that those samples are collected, handled, and used with integrity.

For researchers and sponsors, understanding the ethical framework governing biospecimen procurement is not optional—it’s foundational.

Why Ethics Matter in Biospecimen Research

Ethical biospecimen practices are critical for:

  • Protecting donor rights and privacy
  • Ensuring regulatory compliance
  • Maintaining scientific integrity
  • Building long-term trust across the research ecosystem

Failures in this area don’t just create compliance risk—they can undermine entire research programs.

The Core Ethical Framework

Ethical biospecimen procurement is built on a combination of governance, transparency, and accountability. Several key documents and processes form the foundation.

Informed Consent: The Cornerstone

Informed consent ensures that donors understand—and agree to—how their biological materials will be used.

A robust consent process should clearly explain:

  • How and where samples will be collected
  • How samples will be stored, used, and potentially shared
  • Risks and potential benefits
  • The donor’s rights, including the ability to withdraw consent
  • How privacy and confidentiality are protected

This process reflects a core ethical principle: respect for autonomy

Institutional Review Boards (IRBs): Independent Oversight

Institutional Review Boards (IRBs) are responsible for reviewing and approving research involving human biospecimens.

Their role includes:

  • Evaluating scientific merit and ethical balance
  • Ensuring appropriate consent procedures
  • Protecting donor privacy and welfare
  • Monitoring ongoing compliance

IRBs provide an essential layer of independent oversight—ensuring that research meets both ethical and regulatory standards.

Nondisclosure Agreements (NDAs): Protecting Confidentiality

NDAs are used to safeguard sensitive information, including:

  • Proprietary research data
  • Intellectual property
  • Donor-related information (where applicable)

These agreements define what information is protected, who can access it, and the consequences of misuse.

Material Transfer Agreements (MTAs): Governing Sample Use

Material Transfer Agreements (MTAs) define the terms under which biospecimens are shared between parties.

They typically address:

  • Ownership and permitted use of materials
  • Distribution and sharing restrictions
  • Publication and intellectual property rights
  • Compliance with ethical and regulatory requirements

MTAs are critical for aligning expectations—and avoiding downstream disputes.

Common Questions in Practice

Who owns the data generated from biospecimens?

Ownership is typically defined in the Material Transfer Agreement (MTA).

This agreement outlines:

  • Data ownership rights
  • Publication rights
  • Intellectual property considerations

There is no universal rule—only what is contractually agreed.

Do you need your own IRB to use externally sourced samples?

It depends on the nature of the samples:

  • De-identified samples: May not require additional IRB oversight
  • Identifiable or linked samples: Typically require IRB approval or exemption

Requirements can vary, so alignment with regulatory guidance and institutional policies is essential.

Can samples be shared with third parties?

Only if permitted under the MTA.

Sharing restrictions often include:

  • Limits on redistribution
  • Requirements for additional approvals
  • Obligations to maintain ethical and regulatory compliance

Legal review is strongly recommended before any third-party transfer.

How ABS Bio Approaches Ethics and Compliance

At ABS Bio, ethical procurement is embedded into every stage of the biospecimen lifecycle.

Our approach includes:

  • Strict adherence to informed consent and donor protections
  • Robust governance aligned with IRB and regulatory requirements
  • Clear contractual frameworks (NDAs, MTAs) to define rights and responsibilities
  • End-to-end traceability and documentation

This ensures that every sample is not only high quality—but ethically and legally sound.

Conclusion

Ethics in biospecimen research is not a formality—it’s a prerequisite.

As research becomes more complex and data more valuable, the importance of clear ethical frameworks will only increase. Organizations that prioritize ethical rigor are better positioned to:

  • Protect donors
  • Reduce risk
  • Enable collaboration
  • Deliver credible, defensible science

Ultimately, ethical discipline is what allows innovation to scale responsibly.

Other FAQ

What is ethical human biospecimen procurement?
Ethical human biospecimen procurement involves obtaining biological samples under informed consent, regulatory oversight, and strict donor privacy protections.

Why is informed consent important in biospecimen research?
Informed consent ensures donors understand how their samples may be collected, stored, used, and shared for research purposes.

What role does an IRB play in biospecimen research?
An Institutional Review Board reviews research protocols to ensure donor rights, privacy, and welfare are protected.

What is a Material Transfer Agreement (MTA)?
An MTA defines the legal and ethical terms governing the transfer, use, ownership, and sharing of biospecimens and related data.

Published On: June 23, 2026

HARMINDER SINGH, M.D.

Business Development Director, ABS Bio

15+ years in life sciences

Biospecimen operations expert

Precision medicine research

Harminder Singh, M.D. is Business Development Director at ABS Bio. He joined ABS Bio from Cureline, where he was instrumental in leading biospecimen operations. He brings more than 15 years of experience in the life sciences industry and is a recognized expert in human biospecimen sourcing, management, and global clinical research. Dr. Singh is actively engaged in designing and executing research projects involving human biospecimens to help develop precision medicine therapies. He has a strong track record of building and maintaining long-term partnerships with clinical networks and pharmaceutical/biotechnology clients.